10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
Viking Therapeutics Inc. (VKTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 4,432,142 | $144,221,901 | +109% | 0.12% |
| 2. | D E Shaw D. E. Shaw | 1,676,713 | $54,560,241 | -3% | 0.03% |
| 3. | Citadel Investment Group Ken Griffin | 1,262,221 | $41,072,672 | -28% | 0.01% |
| 4. | 924,600 | $30,086,484 | -36% | 0% | |
| 5. | Vestal Point Capital Ryan Wilder | 914,147 | $29,746,343 | 0.83% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.50 | 4,475 | $149,912.50 | 4,475 | 2026-03-10 | Filing | |
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $2.47 | 45,000 | $111,195.00 | 111,250 | 2022-05-02 | Filing | |
| $5.69 | 20,000 | $113,800.00 | 66,250 | 2021-06-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.09 | 1,500 | $48,133.05 | 189,891 | 2026-01-05 | Filing | |
| $34.24 | 10,300 | $352,634.92 | 191,371 | 2026-01-05 | Filing | |
| $33.38 | 13,900 | $464,020.92 | 201,671 | 2026-01-05 | Filing | |
| $32.30 | 31,961 | $1,032,180.50 | 215,571 | 2026-01-05 | Filing | |
| $35.07 | 1,600 | $56,116.96 | 409,190 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,880,290 | $223,884,622 | 0% | |
| 2. | 6,024,753 | $196,045,469 | 0.01% | |
| 3. | 5,012,502 | $163,106,815 | 0% | |
| 4. | 4,464,298 | $145,268,257 | 0% | |
| 5. | 4,395,557 | $143,031,425 | 0% |
News See All
Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?
Is VKTX a good stock to buy? We came across a bullish thesis on Viking Therapeutics, Inc. on Charlie Evans’s Substack by Charlie Evans PhD.
20 Stocks Jim Cramer Wanted You To Sell & Immediately Get Out Of
As hostilities in Iran are restrained by a ceasefire, Jim Cramer has been busy discussing the current geopolitical climate and its impact on markets.
Jim Cramer's Hottest GLP-1 and Weight Loss Stock Picks
In an appearance on CNBC's Fast Money in January, Ray Stevens, CEO of Structure Therapeutics, discussed the unmet potential in the obesity market.
Is Viking Therapeutics (VKTX) One of the Shorted Biotech Stocks to Invest in
On February 12, Michael Ulz from Morgan Stanley reduced his price target on Viking Therapeutics Inc. (NASDAQ:VKTX) from $102 to $99.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Raymond James Lowers Viking Therapeutics, Inc. (VKTX) Price Target Amid Optimistic Clinical Initiative Outlook
Viking Therapeutics, Inc. (NASDAQ:VKTX) ranks among the most shorted stocks to buy according to analysts.
11 Most Shorted Stocks to Buy According to Analysts
Although holes are starting to form, the stock market doesn't seem to be in danger of crashing just yet, with the S&P 500 down only 1% from its record high.
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled.
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026Viking Therapeutics, Inc. misses on earnings expectations.
Hedge Fund Resource Center